Novo Nordisk to create the world's first all-diabetes professional cycling team

Novo NordiskNovo Nordisk announced a unique partnership to form Team Novo Nordisk, a global sports team with more than 100 cyclists, triathletes and runners who all have diabetes, spearheaded by the world's first all-diabetes pro-cycling team.

Team Novo Nordisk will use life experiences and competitiveness to motivate people affected by diabetes. Throughout 2013, these athletes will compete in more than 500 sporting competitions around the world. The men's pro-cycling team will compete in races such as the USA Pro Cycling Challenge, the Tour of Britain and the Paris-Tours, with the ultimate goal of joining the Tour de France.

"As part of our long-standing Changing Diabetes® programme, this partnership provides a tremendous opportunity to raise awareness, and educate, empower and inspire people with diabetes," says Jakob Riis, senior vice president, Global Marketing and Global Medical Affairs, Novo Nordisk. "This is yet another way Novo Nordisk is striving to create more opportunities to live well with diabetes."

Phil Southerland founded what was known as 'Team Type 1' in 2005 and included riders and athletes with and without diabetes until this year. The new Team Novo Nordisk will only comprise of athletes who have diabetes and will continue to grow the team mission "to instil hope and inspiration for people around the world affected by diabetes."

"As Team Novo Nordisk we want to show the world what is possible with great diabetes control. Between us, Team Novo Nordisk has over 1,000 diagnosed years of diabetes with no complications and we stand for what life with diabetes can be like," Southerland says. "Exercise is that billion dollar drug that nobody ever gets prescribed, and in my experience is the best of them all. With appropriate diet, exercise, treatment and technology, anyone with diabetes can achieve their dreams."

About Diabetes
Today, 371 million people are living with diabetes.(1) Changing Diabetes® is Novo Nordisk's global commitment to improve conditions for the millions of people who live with diabetes around the world today, and those who are at risk of developing diabetes tomorrow. It is a global advocacy and partner platform which advocates for the prevention and early detection of diabetes, as well as improved treatment, care and health outcomes.

Headquartered in Denmark, Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

1. International Diabetes Federation. IDF Diabetes Atlas, 5th Edition, 2012 Update. Brussels, Belgium: International Diabetes Federation.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]